TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options for Aggressive Stage I and Aggressive, Contiguous Stage II B-Cell Non-Hodgkin Lymphoma
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Context: Treatment of Aggressive Stage I and Aggressive, Contiguous Stage II B-Cell Non-Hodgkin Lymphoma
Treatment options for aggressive stage I and aggressive, contiguous stage II B-cell non-Hodgkin lymphoma include:
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without IF-XRT.
Source links and citations
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice